Pharmacology. 2020 Apr 29:1-10. doi: 10.1159/000506233. [Epub ahead of print]
In a rapidly aging society, the number of people suffering from osteoporosis keeps increasing. However, effective prevention strategies for osteoporosis are not yet currently available.
In this study, we examined the ameliorative effects of tranexamic acid on osteoporosis in 24-month-old mice.
During the study period, mice were orally administered tranexamic acid 3 times per week.
Bone mineral density, which is a parameter of osteoporosis, was improved following tranexamic acid administration. In addition, female mice evidenced a stronger phenotypic improvement than male mice. In female mice treated with tranexamic acid, ovary abnormalities were reduced. Furthermore, the levels of transforming growth factor-β, hyaluronic acid, CD44, reactive oxygen species, and apoptosis, as well as the number of infiltrated neutrophils and macrophages in the ovary were lower than those in the control or solvent-administered mice. In addition, 17β-estradiol levels in blood increased when compared with the control or solvent-treated mice. In addition, administration of tranexamic acid to 24-month-old male mice decreased the level of apoptosis in the testis. However, the levels of 17β-estradiol and testosterone in blood increased compared with the control or solvent-administered mice.
The use of tranexamic acid had an ameliorative effect on osteoporosis, possibly by protecting ovaries and testes.